BR112015008834A2 - método para o tratamento de câncer, método para melhorar o critério do grupo de trabalho(psawg2) método para a inibição da fosforilação, método para a inibição da atividade da proteína quinase, método para a medição da inibição da fosforilação e kit - Google Patents
método para o tratamento de câncer, método para melhorar o critério do grupo de trabalho(psawg2) método para a inibição da fosforilação, método para a inibição da atividade da proteína quinase, método para a medição da inibição da fosforilação e kitInfo
- Publication number
- BR112015008834A2 BR112015008834A2 BR112015008834A BR112015008834A BR112015008834A2 BR 112015008834 A2 BR112015008834 A2 BR 112015008834A2 BR 112015008834 A BR112015008834 A BR 112015008834A BR 112015008834 A BR112015008834 A BR 112015008834A BR 112015008834 A2 BR112015008834 A2 BR 112015008834A2
- Authority
- BR
- Brazil
- Prior art keywords
- phosphorylation
- inhibiting
- psawg2
- kit
- protein kinase
- Prior art date
Links
- 238000000034 method Methods 0.000 title 5
- 230000002401 inhibitory effect Effects 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 title 1
- 230000026731 phosphorylation Effects 0.000 title 1
- 238000006366 phosphorylation reaction Methods 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261715510P | 2012-10-18 | 2012-10-18 | |
| PCT/US2013/065363 WO2014062878A2 (en) | 2012-10-18 | 2013-10-17 | Treatment of cancer with tor kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015008834A2 true BR112015008834A2 (pt) | 2017-07-04 |
Family
ID=50023830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008834A BR112015008834A2 (pt) | 2012-10-18 | 2013-10-17 | método para o tratamento de câncer, método para melhorar o critério do grupo de trabalho(psawg2) método para a inibição da fosforilação, método para a inibição da atividade da proteína quinase, método para a medição da inibição da fosforilação e kit |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140113904A1 (https=) |
| EP (1) | EP2908814B1 (https=) |
| JP (3) | JP2015534981A (https=) |
| KR (2) | KR102157914B1 (https=) |
| CN (2) | CN110721186A (https=) |
| AU (1) | AU2013202768B2 (https=) |
| BR (1) | BR112015008834A2 (https=) |
| CA (1) | CA2888609C (https=) |
| EA (1) | EA029164B1 (https=) |
| ES (1) | ES2777936T3 (https=) |
| IL (1) | IL238326B (https=) |
| MX (1) | MX368407B (https=) |
| MY (1) | MY176599A (https=) |
| NI (1) | NI201500055A (https=) |
| PH (2) | PH12020550858A1 (https=) |
| SG (2) | SG10201810575WA (https=) |
| UA (1) | UA117000C2 (https=) |
| WO (1) | WO2014062878A2 (https=) |
| ZA (1) | ZA201503105B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| EP2945636B1 (en) | 2013-01-16 | 2017-06-28 | Signal Pharmaceuticals, LLC | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| US10189841B2 (en) * | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| CN110403943B (zh) * | 2019-08-19 | 2022-05-17 | 陕西科技大学 | Cc-115在制备抗真菌药物中的应用及其药物组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1159582C (zh) * | 2001-12-08 | 2004-07-28 | 云南大学 | 一种人体全血或血清总前列腺特征性抗原值，总前列腺特征性抗原灰区值检测方法 |
| GB0509748D0 (en) | 2005-05-13 | 2005-06-22 | Univ Glasgow | Materials and methods relating to cell based therapies |
| US20070238745A1 (en) * | 2006-04-07 | 2007-10-11 | University Of South Florida | PI3K-Akt Pathway Inhibitors |
| ATE543819T1 (de) * | 2006-10-19 | 2012-02-15 | Signal Pharm Llc | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit |
| US7968556B2 (en) | 2006-10-19 | 2011-06-28 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| EP2349984A1 (en) * | 2008-10-17 | 2011-08-03 | Merck & Co. | Combination therapy |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| MY177695A (en) * | 2009-10-26 | 2020-09-23 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
| US20120238562A1 (en) * | 2011-03-09 | 2012-09-20 | Cedars-Sinai Medical Center | Treatment of cancer by targeting molecules that influence mst1/stk4 signaling |
-
2013
- 2013-04-06 AU AU2013202768A patent/AU2013202768B2/en active Active
- 2013-10-17 SG SG10201810575WA patent/SG10201810575WA/en unknown
- 2013-10-17 PH PH1/2020/550858A patent/PH12020550858A1/en unknown
- 2013-10-17 MX MX2015004874A patent/MX368407B/es active IP Right Grant
- 2013-10-17 WO PCT/US2013/065363 patent/WO2014062878A2/en not_active Ceased
- 2013-10-17 MY MYPI2015701232A patent/MY176599A/en unknown
- 2013-10-17 CA CA2888609A patent/CA2888609C/en active Active
- 2013-10-17 KR KR1020157012636A patent/KR102157914B1/ko active Active
- 2013-10-17 SG SG11201502999YA patent/SG11201502999YA/en unknown
- 2013-10-17 JP JP2015537809A patent/JP2015534981A/ja active Pending
- 2013-10-17 UA UAA201504749A patent/UA117000C2/uk unknown
- 2013-10-17 ES ES13824539T patent/ES2777936T3/es active Active
- 2013-10-17 CN CN201910935268.7A patent/CN110721186A/zh active Pending
- 2013-10-17 US US14/055,985 patent/US20140113904A1/en not_active Abandoned
- 2013-10-17 EA EA201590744A patent/EA029164B1/ru not_active IP Right Cessation
- 2013-10-17 CN CN201380066349.9A patent/CN105050601A/zh active Pending
- 2013-10-17 EP EP13824539.4A patent/EP2908814B1/en active Active
- 2013-10-17 KR KR1020207026267A patent/KR102267927B1/ko active Active
- 2013-10-17 BR BR112015008834A patent/BR112015008834A2/pt not_active Application Discontinuation
-
2015
- 2015-04-16 IL IL238326A patent/IL238326B/en active IP Right Grant
- 2015-04-17 NI NI201500055A patent/NI201500055A/es unknown
- 2015-04-17 PH PH12015500867A patent/PH12015500867B1/en unknown
- 2015-05-06 ZA ZA2015/03105A patent/ZA201503105B/en unknown
-
2019
- 2019-01-28 JP JP2019012014A patent/JP7162543B2/ja active Active
-
2020
- 2020-11-30 JP JP2020199055A patent/JP2021050213A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015008834A2 (pt) | método para o tratamento de câncer, método para melhorar o critério do grupo de trabalho(psawg2) método para a inibição da fosforilação, método para a inibição da atividade da proteína quinase, método para a medição da inibição da fosforilação e kit | |
| BR112015004547A2 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
| BR112015007214A8 (pt) | composto, método para a inibição da atividade da quinase, método para o tratamento, composição, utilização de um composto e invenção | |
| BR112015001830A2 (pt) | composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção | |
| BR112014032105A2 (pt) | método para o tratamento de câncer | |
| BR112014029404A2 (pt) | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção | |
| DK3628670T3 (da) | Saltform til ezh2-hæmning | |
| BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
| BR112015003004A2 (pt) | análogos de piridazina , 1-4 dissubstituída e métodos para tratar condições relacionadas com deficiência de smn | |
| BR112015002626A2 (pt) | métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa | |
| BR112015002709A2 (pt) | novos compostos de pirrolopirimidina como inibidores de proteínas quinases | |
| IL237558A0 (en) | Methods for the treatment of locally advanced breast cancer | |
| BR112015002085A2 (pt) | proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção | |
| BR112014031806A2 (pt) | método para tratamento de câncer positivo para gd2 | |
| IL232128B (en) | Tor kinase inhibitors for cancer treatment | |
| IL234639A0 (en) | Treatment of cancer with tor kinase inhibitors | |
| IL223201A (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| HUE049620T2 (hu) | Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal | |
| BR112015000649A2 (pt) | compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção | |
| DK2922828T3 (da) | 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer | |
| ZA201501209B (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
| DK3057962T3 (da) | Hydrochloridsaltform til ezh2-hæmning | |
| IL231683B (en) | Methods and systems for identifying and treating anti-progestin sensitive sensitive tumors | |
| BR112014030416A2 (pt) | composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção. | |
| WO2014066125A3 (en) | Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |